Papers of particular interest, published within the period of review, have been highlighted as: • of special interest We are grateful to Sally Lowell and Pablo Navarro for comments on the manuscript and to the Medical Research Council of the UK and CONACYT for support. “
“Current Opinion in Genetics & Development 2013, 23:519–525 This review comes from a themed
issue on Cell reprogramming Edited by Huck Hui Ng and Patrick Tam For a complete overview see the Issue and the Editorial Available online 8th August 2013 0959-437X/$ – see front matter, © 2013 The Authors. Published by Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.gde.2013.06.002 Cell fate is controlled by both extrinsic factors (e.g. signaling molecules) and intrinsic factors DAPT in vivo (e.g. endogenous transcription factors). It has been shown that activation of the LIF-STAT3 and BMP-SMAD signaling pathways are essential for the maintenance of murine embryonic stem cells [1]. Transcription factors (TFs) downstream of the signaling pathways orchestrate with cell type-specific TFs, including Oct4, Sox2 and Nanog that form an auto-regulatory
loop, to govern cell fate [1]. Consistent with such mechanism, studies of TF-mediated reprogramming demonstrated that cell fates can be manipulated by exogenous Everolimus TFs as well. For example, fibroblasts can be induced into pluripotent stem cells (iPSCs) by the Yamanaka factors (Oct4/Sox2/Klf4/c-Myc), or converted to neuronal cells by Brn2/Ascl1/Myt1l [2 and 3]. Mounting evidence demonstrates that extrinsic factors can functionally mimic reprogramming TFs and/or enhance reprogramming process to facilitate cell fate switching. Here, we review these important extrinsic drivers for somatic cell reprogramming. A successful iPSC reprogramming is to Rebamipide re-establish the intrinsic pluripotency transcriptional network in somatic cells.
This network, in which Oct4 plays a pivotal role, involves dozens of pluripotency-associated factors and basal TFs [4]. Several signaling pathways have been reported to regulate the pluripotency of ESCs, indicating that they target certain components of the pluripotency transcriptional network in ESCs. Changes in the chromatin state of pluripotency genes, when driven by transduced factors or other regulators during reprogramming, may allow these signaling pathways to re-establish the pluripotency transcriptional network (Figure 1). We begin this review with a description of some of these key signaling molecules. Inhibition of MEK and glycogen synthase kinase-3 (GSK-3) by small molecule inhibitors PD0325901 and CHIR99021 (2i) completely eliminated spontaneous differentiation of ESCs in the absence of essential pluripotency signaling pathway activation [5]. During reprogramming, PD0325901 was shown to stabilize and help to select fully reprogrammed iPSCs [6].